EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Recordati SpA's enterprise value is $12,710 Mil.
Recordati SpA's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $2,244 Mil. Therefore, Recordati SpA's EV-to-Revenue for today is 5.66.
The historical rank and industry rank for Recordati SpA's EV-to-Revenue or its related term are showing as below:
RCDTF'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.16 Med: 5.41 Max: 8.95
Current: 5.63
During the past 13 years, the highest EV-to-Revenue of Recordati SpA was 8.95. The lowest was 2.16. And the median was 5.41.
RCDTF's EV-to-Revenue is ranked worse than 79.18% of 1023
companies
in the Drug Manufacturers industry
Industry Median: 2.36
vs RCDTF: 5.63
As of today (2024-05-02), Recordati SpA's stock price is $51.60.
Recordati SpA's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $10.73. Therefore, Recordati SpA's PS Ratio for today is 4.81.
Recordati SpA EV-to-Revenue Historical Data
The historical data trend for Recordati SpA's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Recordati SpA's EV-to-Revenue
For the Drug Manufacturers - General subindustry, Recordati SpA's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Recordati SpA's EV-to-Revenue falls into.
Recordati SpA's current Enterprise Value is $12,710 Mil.
Recordati SpA's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,244 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA's share price for today is $51.60.
Recordati SpA's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.73.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Recordati SpA's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Recordati SpA (Recordati SpA) Business Description
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCDTF has been successfully added to your 